在一家生物技术公司的会议室里,科学家们正针对一款抗体-寡核苷酸偶联药物(AOC)分子的棘手问题展开讨论:


为什么它在早期体内模型中的药效始终未达预期?


初步判断认为分子结构在体内不稳定,但问题根源却如同一个令人困惑的“黑匣子”——难道是负责导航的抗体在系统循环中发生了非预期的局部切割?是连接抗体与寡核苷酸的“桥梁”连接子提前断裂?还是寡核苷酸载荷本身存在代谢不稳定?


由于无法准确定位“薄弱环节”,结构优化无从下手。更棘手的是,这种机制层面的不确定性严重阻碍了后续药代/毒代动力学(PK/TK)研究的开展,因为缺乏明确的生物分析策略,无法确定究竟该对生物基质中的哪些完整分子、释放出的载荷或下游代谢物进行定量监测。


在多方寻求解决方案未果后,这家公司抱着一线希望,找到了药明康德DMPK团队。最终在药明康德复杂合成分子精密分析平台的助力下,成功破解了这款AOC分子的“黑匣子”谜题,为分子结构的优化指明了方向,后续研究工作也得到了顺利推进。



近年来,AOC作为继抗体偶联药物(ADC)之后的一种新的偶联药物形态,正步入产业聚光灯下。凭借精准靶向肝外组织的潜力,AOC为突破核酸药物的递送瓶颈带来了新的希望。


然而,AOC分子由抗体、连接子和寡核苷酸三部分构成,其复杂的体内行为对药物代谢与药代动力学(DMPK)研究构成巨大挑战,而这恰恰是决定其能否成功转化的关键。为此,药明康德DMPK团队凭借丰富的前沿赋能经验与完备的技术仪器平台,针对AOC药物的PK特性与开发痛点量身打造了一站式药代动力学研究平台,以专业的整合策略,助力客户的AOC项目高效转化与快速推进。


“双轨并行”的高分辨方案,破解复杂分子的“黑匣子”


药明康德DMPK团队此前已针对AOC分子的结构特性,运用液相色谱-高分辨质谱(LC-HRMS)平台,构建了“AOC多维生物转化表征平台”。接手项目后,团队迅速调动该平台,启动AOC综合表征策略,力图破解该AOC分子在体内代谢的“黑匣子”。


传统的研究思路往往仅从单一视角进行表征,难以全面捕捉AOC在体内的复杂变化。针对这一挑战,团队采取了“双轨并行”的高分辨分析方案,像侦探一样不放过任何蛛丝马迹:


在蛋白质层面,研究团队对血浆和组织样本中的AOC进行了完整蛋白(Intact)及亚基(Sub-unit)层面的精确质量数扫描,动态追踪药物抗体比(DAR值)的变化,以判断整体偶联结构的血浆稳定性。


在寡核苷酸维度上,通过针对不同检测对象差异化优化的前处理策略结合质谱分析,团队刻画了总寡核苷酸(Total Oligo)、释放的游离寡核苷酸(Released Oligo)以及仍挂载抗体上的结合型寡核苷酸(Conjugated Oligo)的代谢产物图谱,还原了寡核苷酸在体内的完整轨迹。


锁定“元凶”:连接子才是真正的薄弱环节


在深入的代谢产物鉴定(MetID)过程中,一个关键发现扭转了局势。


此前,客户一直怀疑是新合成的寡核苷酸序列在体内不够稳定。然而,借助高分辨质谱的关键数据,药明康德DMPK团队在高分辨率视野下,清晰捕捉到了一个意料之外的代谢产物,由此锁定了真正的原因——连接子。


分析结果证实,该连接子在药物抵达靶细胞之前,已经在血液中发生了提前裂解。随后,研究团队利用高分辨质谱提供的信息,精准锁定了连接子断裂的具体位点。


这一发现非常关键。如果没有直接的分析证据,只考虑继续修改寡核苷酸序列,则会导致真正的血浆不稳定隐患无法被解决。反之,LC-HRMS的结果直接从机理上解释了AOC药效不佳的原因——即载荷被提前释放——并迅速将优化方向引向了连接子的化学设计。


为AOC开发带来的三大关键贡献


明确连接子提前裂解的机制,为该分子的后续开发提供了三个方面的关键支持:


第一,明确了连接子的优化方向。在明晰提前释放机制及具体断裂位点后,助力客户成功合成出更稳定的新型连接子,解决药物在血浆中不稳定的隐患。


第二,避免了载荷的盲目修改。原有寡核苷酸的稳定性得到确证,无需再担忧其结构问题,为客户节省了大量重新设计序列的时间与成本。


第三,敲定了PK/PD分析策略。清晰的代谢途径鉴定结果为后续IND申报制定了科学的定量分析靶标。


在精准代谢表征数据的指导下,优化后的AOC分子通过维持系统循环稳定性,确保了高效的靶向递送,其体内药效显著提升,结构稳定性也得到充分验证。该项目顺利跨越早期临床前研发阶段,稳步向IND阶段迈进。


图片来源:123RF


这次合作不仅为客户提供了及时的关键支持、切实破解了困局,更搭建起一座信任的桥梁。该客户项目负责人曾表示:“药明康德DMPK团队和他们的高分辨质谱平台,是我们AOC管线研发路上的灯塔。”随后,客户也将优化后分子的后续DMPK评估及推进工作,继续交由药明康德DMPK团队负责。


从“黑匣子”到IND,DMPK如何打通复杂分子转化路径


随着AOC、多肽偶联寡核苷酸(POC)等新型疗法不断涌现,药物分子的复杂度正以前所未有的速度攀升。面对复杂偶联分子在体内多样的存在形式与多变的行为路径,系统化、定量化、可预测的DMPK解析能力,日益成为支持分子转化决策、穿越研发“死亡之谷”的关键一环。


围绕AOC这一复杂分子形式,药明康德DMPK团队依托高端分析仪器平台和深厚的药物分析研究积累,建立了覆盖体外ADME研究、体内PK评价及生物分析方法开发的系统化能力体系,可针对AOC由抗体、连接子与寡核苷酸三部分构成所带来的多维度代谢与分布挑战,设计匹配的研究策略。基于对AOC结构特征与ADME行为关系的深入理解,团队能够支持代谢产物鉴定、暴露-效应关系分析及PK研究方案优化,并为连接子类型选择、偶联位点设计及寡核苷酸修饰策略提供数据支持,从而在体内稳定性、靶向递送与细胞内释放之间实现平衡。


依托跨平台检测技术与寡核苷酸DMPK研究经验的协同整合,该能力体系不仅能解析AOC在ADME过程中的关键行为特征,还可贯穿发现、临床前及临床阶段,为客户在新型偶联药物开发中提供兼具科学深度与转化导向的一体化DMPK解决方案,加速复杂新分子从机制验证迈向临床转化。


这一案例,也是药明康德通过复杂合成分子精密分析平台赋能客户的缩影。该平台拥有上千台高端分析仪器设备、分布于全球多个研究实验室、共覆盖60余种分析类目,随时准备为客户分子的复杂问题提供快速、准确、多维度的解决方案;同时,还能针对共价抑制剂、蛋白降解靶向嵌合体、多肽、寡核苷酸、脂质纳米颗粒(LNP)、ADC与融合蛋白等10余种新分子类型,提供定制分析与纯化方案,满足客户不同研发阶段的需求。


如今,借助精密分析仪器的“慧眼”,越来越多的复杂分子不再是被卡在研发早期的“黑匣子”,而是成为能够被精准解析、稳步推向临床的清晰路径。未来,面对日益增多的复杂分子,药明康德将持续结合灵活、多维度、定制化的技术能力与长期深度的赋能经验,与全球合作伙伴携手,将复杂分子难题转化为清晰的开发路径,助力客户加速更多创新疗法从实验室走向临床,早日惠及患者。




Cracking the AOC “Black Box”: How WuXi AppTec’s DMPK Team Pinpoints Structural Liabilities with Precision Analytical Tools


Key Takeaways

  • Antibody-oligonucleotide conjugates (AOCs) present unique DMPK challenges because their in vivo disposition is determined by three interconnected components: the antibody, linker, and oligonucleotide payload.

  • In this case, WuXi AppTec’s DMPK team used liquid chromatography-high-resolution mass spectrometry (LC-HRMS) to identify premature linker cleavage in systemic circulation as the root cause of poor in vivo performance, rather than metabolic instability of the oligonucleotide payload.

  • The resulting data guided the rational design of a more stable second-generation linker, avoided unnecessary oligonucleotide sequence redesign, and defined appropriate analytes for subsequent PK/PD and IND-enabling studies.

  • The optimized second-generation AOC achieved significant improvement in in vivo efficacy by maintaining systemic stability for target-mediated delivery, and subsequently advanced toward the IND stage.

  • WuXi AppTec’s DMPK capabilities for complex conjugated molecules span in vitro ADME, in vivo PK, bioanalysis, metabolite identification, and multidimensional LC-HRMS characterization across discovery, preclinical, and clinical development.


Following the rise of antibody-drug conjugates (ADCs), another class of conjugated therapeutics—antibody-oligonucleotide conjugates (AOCs)—is attracting growing attention. With the potential for precise extrahepatic targeting, AOCs offer new hope for overcoming the delivery bottlenecks that have long constrained nucleic acid therapeutics.


AOCs, however, are structurally and biologically complex. Each molecule contains three key components—an antibody, a linker, and an oligonucleotide—and the stability and behavior of each component can influence the overall pharmacokinetic and pharmacodynamic profile.


This complexity creates significant challenges for drug metabolism and pharmacokinetics (DMPK) studies. Understanding how an AOC changes after administration, where it is distributed, how its linker behaves, and whether its payload remains intact can be critical for determining why a candidate succeeds or fails during preclinical development.


Recently, a biotechnology company encountered exactly this challenge.


One of its AOC candidates consistently demonstrated lower-than-expected efficacy in early in vivo models. Initial investigations suggested poor structural stability in vivo, but the exact underlying cause remained elusive.


Was the targeting antibody undergoing unintended in vivo clipping in systemic circulation? Was the linker connecting the antibody and oligonucleotide cleaving prematurely? Or was the oligonucleotide payload itself metabolically unstable?


Without elucidating the specific structural liabilities, there was no clear path for rational molecule optimization. Furthermore, this mechanistic uncertainty complicated subsequent pharmacokinetic and toxicokinetic (PK/TK) studies, as the company lacked a definitive bioanalytical strategy regarding which intact molecular species, released payloads, or downstream metabolites should be quantitatively monitored in biological matrices. After exploring multiple potential solutions without success, the company turned to WuXi AppTec’s DMPK team.



Dual-Track High-Resolution Strategy: Cracking the AOC “Black Box”


WuXi AppTec’s DMPK team had previously developed a multidimensional AOC biotransformation characterization platform based on liquid chromatography-high-resolution mass spectrometry (LC-HRMS).


The platform was designed specifically to address the structural complexity of AOCs and characterize changes occurring across their antibody, linker, and oligonucleotide components.


For this project, the team implemented a comprehensive analytical strategy to determine the complete biotransformation profile of the AOC in vivo.


Traditional approaches may characterize a complex conjugated molecule from only one analytical perspective. For AOCs, however, evaluating only a single component provides an incomplete picture of the molecule's in vivo behavior. Fully capturing their dynamic fate requires a hierarchical analytical strategy that assesses both the holistic conjugate structure and the distinct oligonucleotide populations present within the biological matrix.


WuXi AppTec adopted a dual-track, high-resolution analytical approach.


At the protein level, the team performed intact protein analysis of AOCs in plasma. The researchers also monitored changes in the drug-to-antibody ratio (DAR) over time to evaluate the plasma stability of the overall antibody-conjugate structure.


At the oligonucleotide level, differentially optimized sample preparation combined with MS methods were employed to accurately characterize three important molecular populations: 


  • Total oligonucleotide (Total Oligo) 

  • Released oligonucleotide (Released Oligo) 

  • Antibody-conjugated oligonucleotide (Conjugated Oligo)


Together, these measurements enabled the team to reconstruct the comprehensive biotransformation profile of the AOC in vivo and clearly distinguish among the intact conjugate, the released payload, and its downstream metabolites.


Pinpointing the Root Cause: The Linker Was the Primary Liability 


During in-depth metabolite identification (MetID), the team made a finding that pivoted the direction of the project.


The client had suspected that the newly synthesized oligonucleotide sequence was insufficiently stable in vivo. However, with LC-HRMS data, the team elucidated an unexpected metabolite, which led them to the true cause—the linker. The analysis confirmed that the linker was undergoing premature cleavage in the bloodstream before the AOC could be internalized by target cells. 


Detailed MS and MS/MS spectra generated by high-resolution mass spectrometry then allowed the researchers to identify the specific site of linker cleavage.


This distinction was important. Without direct analytical evidence, the development team could have continued redesigning the oligonucleotide sequence while leaving the actual source of plasma instability unresolved.


Instead, the LC-HRMS findings established a clear mechanistic explanation for the AOC's poor in vivo performance—which resulted in the prematurely released payload and consequent loss of efficacy—and redirected the optimization strategy toward linker chemistry.


Three Key Contributions to AOC Development


Identification of the premature linker-cleavage mechanism provided three important benefits for subsequent development.


First, it established a clear direction for linker optimization.


Once the mechanism and specific cleavage site were identified, the client was able to design and successfully synthesize a more stable second-generation linker.


Second, it prevented unnecessary modification of the oligonucleotide payload.


The analysis confirmed that the original oligonucleotide itself was sufficiently stable. The client therefore did not need to undertake extensive sequence redesign, avoiding unnecessary development time and cost.


Third, it helped define the bioanalytical strategy for PK/PD assessment. 


Characterization of the molecule's metabolic pathways clarified which molecular species and metabolites should be monitored quantitatively in subsequent pharmacokinetic studies and IND-enabling development.


In this case study, LC-HRMS-guided linker optimization resulted in a second-generation AOC that achieved approximately a twofold improvement in in vivo efficacy. Its improved structural stability was also confirmed.


Image Source: 123RF


The program subsequently progressed beyond early preclinical development and advanced steadily toward the IND stage.


The success also led to continued collaboration between the two organizations. The client's project leader commented:


“WuXi AppTec’s DMPK team and its high-resolution mass spectrometry platform have been a beacon for the development of our AOC pipeline.”


The client subsequently continued to work with WuXi AppTec’s DMPK team on the DMPK evaluation and development of the optimized molecule.


From “Black Box” to IND: How DMPK Paves the Way for Complex Molecule Translation


As emerging modalities such as AOCs and peptide-oligonucleotide conjugates (POCs) advance, drug developers increasingly need to understand complex and dynamic molecular forms in vivo.


For conjugated therapeutics, a single administered molecule may generate multiple species during absorption, distribution, metabolism, and excretion. These may include intact conjugates, partially deconjugated forms, released payloads, linker-stub metabolites, and downstream oligonucleotide metabolites.


As a result, DMPK characterization is increasingly important for answering several development-critical questions:


  • Is the intact conjugate sufficiently stable in systemic circulation?

  • Does the molecule reach target tissues (target-mediated disposition)?

  • When and where is the oligonucleotide released and further metabolized?

  • Which metabolites are formed in vivo?

  • Which molecular species should be quantitated in PK and TK studies?

  • How do linker design, conjugation site, and oligonucleotide modification affect systemic and target tissue exposure and pharmacological activity?


Systematic, quantitative, and predictive DMPK analysis can therefore support rational molecular optimization and translational decision-making throughout development.


WuXi AppTec’s DMPK Capabilities for AOC Development


For AOCs, WuXi AppTec’s DMPK team has established capabilities covering in vitro ADME studies, in vivo PK evaluation, bioanalytical method development, and multidimensional metabolite identification.


These capabilities are designed to address the three-component architecture of AOCs—the antibody, linker, and oligonucleotide—and the resulting challenges associated with metabolism, distribution, stability, and payload release.


Based on an understanding of the relationship between AOC structural features and ADME behavior, the team integrates multidimensional biotransformation characterization with robust quantitative bioanalysis to support: 


  • Evaluation of linker stability to pinpoint liabilities and prevent premature in vivo cleavage; 

  • Assessment of conjugation-site strategies to determine their impact on conjugate integrity and systemic exposure; 

  • Characterization of chemical oligonucleotide modifications to optimize the payload’s metabolic stability and tissue persistence; 

  • Data-driven PK study design and exposure-response analysis tailored to the diverse molecular species generated in vivo.


By integrating cross-platform analytical technologies with experience in oligonucleotide DMPK, WuXi AppTec can support AOC programs across discovery, preclinical, and clinical development, providing integrated DMPK solutions with both mechanistic and translational relevance.


A Microcosm of Platform Innovation: Beyond AOCs


This AOC project also illustrates the broader role of WuXi AppTec’s precision analytical platform for complex synthetic molecules.


The platform includes more than 1,000 advanced analytical instruments distributed across multiple research laboratories worldwide and covers more than 60 categories of analytical capabilities. These resources are designed to provide rapid, accurate, and multidimensional analytical solutions for complex structural challenges.


The platform can also provide customized analytical, purification, and related solutions for more than 10 emerging molecular modalities. Beyond AOCs, the platform also supports the analysis for other complex modalities including covalent inhibitors, proteolysis-targeting chimeras, peptides, oligonucleotides, liposomes and lipid nanoparticles (LNPs), ADCs, and fusion proteins.


These capabilities can support different stages of drug development as molecular complexity increases.


Today, with the keen “eyes” of precision analytical instruments, an increasing number of complex molecules are no longer stuck in the “black box” of empirical discovery. Instead, they are being transformed into clearly defined development pathways, with precision analysis guiding their progress toward the clinic. 


Looking ahead, WuXi AppTec will continue to combine advanced analytical instrumentation with flexible, multidimensional, and customized technical capabilities to address increasingly complex drug-development challenges.


By working with partners worldwide, WuXi AppTec aims to turn difficult molecular questions into actionable development strategies, helping clients advance innovative therapies from laboratory research toward clinical development and, ultimately, to patients.



免责声明:本文仅作信息交流之目的,文中观点不代表药明康德立场,亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导,请前往正规医院就诊。


版权说明:欢迎个人转发至朋友圈,谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”,获取转载须知。


分享,点赞,在看,聚焦全球生物医药健康创新